| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6125196 | Osteoarthritis and Cartilage | 2013 | 9 Pages |
Abstract
Fasitibant prevents B2 receptor-mediated activation and sensitization of peripheral joint afferents and the ensuing inflammatory hyperalgesia, and may be a useful, novel drug for arthritis pain treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
A. Gomis, S. Meini, A. Miralles, C. Valenti, S. Giuliani, C. Belmonte, C.A. Maggi,